Chiron initiates phase I/II study of influenza cell culture vaccine in US

摘要

Chiron Corporation has initiated a phase I/II study of an investigational cell culture-derived influenza vaccine in the United States.Cell culture-derived influenza vaccine (commonly referred to as 'flu cell culture' vaccine) represents the next generation of influenza vaccine,both for annual vaccine production and for long-term pandemic preparedness.